VBLT Key Statistics, Chart & Performance
The current stock price of VBLT is 0.156 USD. In the past month the price decreased by -34.45%. In the past year, price increased by 15.56%.
VBLT Latest News, Press Relases and Analysis
VBLT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24 | 400.88B | ||
| AMGN | AMGEN INC | 14.97 | 176.29B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.28 | 115.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.76 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.29B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.44 | 25.64B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 22.27B | ||
| INCY | INCYTE CORP | 16 | 20.16B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.32B |
Related stock screener links
About VBLT
Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. It's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Company Info
VASCULAR BIOGENICS LTD
8 HaSatat St.
Or Yehuda 7178106 IL
CEO: Dror Harats
Employees: 7
Phone: 97236346450.0
VASCULAR BIOGENICS LTD / VBLT FAQ
Can you describe the business of VASCULAR BIOGENICS LTD?
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. It's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
What is the current price of VBLT stock?
The current stock price of VBLT is 0.156 USD. The price decreased by -8.77% in the last trading session.
Does VBLT stock pay dividends?
VBLT does not pay a dividend.
What is the ChartMill technical and fundamental rating of VBLT stock?
VBLT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for VASCULAR BIOGENICS LTD?
VASCULAR BIOGENICS LTD (VBLT) has a market capitalization of 12.11M USD. This makes VBLT a Nano Cap stock.
Can you provide the ownership details for VBLT stock?
You can find the ownership structure of VASCULAR BIOGENICS LTD (VBLT) on the Ownership tab.
VBLT Technical Analysis
VBLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VBLT. VBLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VBLT Financial Highlights
Over the last trailing twelve months VBLT reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS increased by 56.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.74% | ||
| ROE | -82.94% | ||
| Debt/Equity | 0 |
VBLT Forecast & Estimates
7 analysts have analysed VBLT and the average price target is 5.1 USD. This implies a price increase of 3169.23% is expected in the next year compared to the current price of 0.156.
For the next year, analysts expect an EPS growth of -15.38% and a revenue growth 68.85% for VBLT